October 25, 2021
The University of Cincinnati's Dr. Xiaoting Zhang has been awarded a patent for a novel RNA nanoparticle treatment for breast cancer.
October 21, 2021
Dr. Annie Brown spoke with WVXU about the need for better health data and research of transgender populations, breast cancer screening recommendations and how to make screening care more welcoming for all patients.
October 26, 2021
The University of Cincinnati's Dr. Annie Brown was featured in an MSN article detailing the push for the passage of Ohio House Bill 371, which would require insurance companies to cover dense breast tissue screenings.
November 12, 2021
Local 12 featured Dr. Christopher Radchenko and Dr. Alejandro Aragaki in a story about new robotic-assisted bronchoscopy techniques available that should help diagnose lung cancer sooner.
October 11, 2021
The University of Cincinnati is opening a new clinical trial looking to see how the combination of immunotherapy and transplant can improve patient outcomes.
September 30, 2021
University of Cincinnati researchers have joined a nationwide clinical trial exploring the effectiveness of personalized treatments for patients with acute myelogenous leukemia (AML), a cancer of the blood and bone marrow.
October 14, 2021
UC's Dr. Annie Brown discusses breast cancer screening recommendations for transgender patients and ways to make care more accessible and equitable.
March 9, 2022
Inside Precision Medicine featured recent University of Cincinnati research led by Dr. Trisha Wise-Draper showing adding immunotherapy to standard of care treatments for head and neck cancer increased survival rates for intermediate risk patients.
February 25, 2022
University of Cincinnati researchers led by Jiajie Diao and Yujie Sun have developed a new pH probe and imaging technique to provide researchers more information when studying diseases like cancer and Alzheimer's.
February 28, 2022
Researchers led by the University of Cincinnati's Dr. Trisha Wise-Draper led a clinical trial that showed immunotherapy drug pembrolizumab increased survival rates for head and neck cancer patients with intermediate risk.